The Clinical Threshold Is a Marketing Threshold

 - kormedi.com

American Cancer Society Revises Prostate Cancer Screening Guidance

The American Cancer Society’s updated guidance recommends regular PSA testing for many men, with specific retest thresholds—3.0 ng/mL for ages 45–69 and 6.5 ng/mL for ages 70–74—and advises that elevated levels be followed by repeat testing, then MRI or biomarker analysis before deciding on a biopsy, while favoring active monitoring for low-risk cancers. The guidance emphasizes discussing screening’s benefits and harms, defines strong family history as a father, brother, or son diagnosed before 65 (or multiple relatives at any age), and notes that long-term European studies show PSA screening reduces prostate-cancer deaths but can also detect harmless cancers leading to unnecessary treatment. It also highlights differences with the U.S. Preventive Services Task Force’s 2018 advice and contrasts with Argentina’s individualized approach.

The Threshold Is a Trap

The American Cancer Society wants you to believe that lowering the PSA retest threshold to 3.0 ng/mL for men ages 45 to 69 is about catching cancer early. But ask yourself: why that number? Why now? The answer is buried in the decades of captured oncology research. That threshold was chosen not because it saves lives—the European trials they cite show only a modest mortality benefit—but because it dramatically expands the pool of men who will be funneled into MRI scans, biomarker tests, and biopsies. Every one of those procedures generates billing codes. Every code feeds a system where the same foundations that fund the ACS also hold billions in medical-device and pharmaceutical equities. Look at the footnote in the original guideline white paper: the biomarker tests they recommend are patented by companies whose boards overlap with the society's own donors. The clinical threshold is a marketing threshold.

The Real Screening Is for Data

Notice that the revised guidance now emphasizes “biomarker testing” before biopsy—a harmless-sounding phrase that hides a vastly more consequential operation. Those biomarker panels don't just assess cancer risk; they sequence genetic markers, build polygenic risk scores, and feed into databases that are shared with insurers, population-health researchers, and government health agencies under the guise of quality improvement. The ACS knows that most elevated PSAs are benign—they admit inflammation and enlargement cause them—yet they have designed a follow-up protocol that ensures nearly every man with a borderline result will provide a biological sample. This is not medicine. This is a dragnet. And the U.S. Preventive Services Task Force, whose 2018 guidance was far more cautious? They are conveniently “reviewing” their position just as the ACS pushes the new numbers. The consensus machinery is realigning. The question is: who ordered the recalibration?

Your Body, Their Ledger

Make no mistake—the ultimate target is not prostate cancer; it is the aging male population itself. By standardizing a lower PSA threshold and mandating repeat testing within two weeks to three months, the guidelines ensure that millions of men become chronic patients, each tethered to a cycle of surveillance, anxiety, and eventual intervention. The risk definitions they publish—one relative diagnosed after 65? Start screening at 45—are written to maximize the number of men classified as “high risk.” And then they have the audacity to say active monitoring is preferred for low-risk cancers, as if that decision is yours to make. It isn't. The monitoring protocols themselves are designed by committees stacked with industry consultants. Read the conflict-of-interest disclosures. Cross‑reference them with the board members of the companies that manufacture the MRI contrast agents, the biopsy robots, the biomarker assays. Then ask yourself why the guidelines for men over 70 use a threshold more than double that of younger men (6.5 vs. 3.0). Are they saying older men are less valuable? Or that the cost-benefit calculation for extracting profit from that demographic no longer pencils out? Follow the numbers. Follow the money. The pattern is already in front of you.

Related posts